C H van Dyck - JoVE Visualize

Showing results (31-40 of 41) with videos related to

Pageof 5

Sort By:

Psychiatry Research|April 18, 2001

Reproducibility of in vivo brain measures of 5-HT2A receptors with PET andJ C Soares, C H van Dyck, P Tan, et al.

Nuclear Medicine and Biology|January 11, 2001

Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigmC H van Dyck, J C Soares, P Z Tan, et al.

Neurology|September 16, 2011

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseS Salloway, R Sperling, R Keren, et al.

Biological Psychiatry|December 4, 1998

Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomographyR T Malison, L H Price, R Berman, et al.

Psychiatry Research|January 21, 2000

[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophreniaN P Verhoeff, J C Soares, C D D'Souza, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 20, 1996

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjectsM Laruelle, A Abi-Dargham, C H van Dyck, et al.

Neurology|November 20, 2009

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseS Salloway, R Sperling, S Gilman, et al.

The Journal of Prevention of Alzheimer'S Disease|March 22, 2023

Investigating Partially Discordant Results in Phase 3 Studies of AducanumabC Mallinckrodt, Y Tian, P S Aisen, et al.

The Journal of Prevention of Alzheimer'S Disease|May 11, 2022

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseS Budd Haeberlein, P S Aisen, F Barkhof, et al.

The Journal of Prevention of Alzheimer'S Disease|October 1, 2024

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease TrialsS Walter, O Langford, G A Jimenez-Maggiora, et al.

Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:

Pageof 5

Psychiatry Research|April 18, 2001

Reproducibility of in vivo brain measures of 5-HT2A receptors with PET andJ C Soares, C H van Dyck, P Tan, et al.

Nuclear Medicine and Biology|January 11, 2001

Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigmC H van Dyck, J C Soares, P Z Tan, et al.

Neurology|September 16, 2011

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseS Salloway, R Sperling, R Keren, et al.

Biological Psychiatry|December 4, 1998

Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomographyR T Malison, L H Price, R Berman, et al.

Psychiatry Research|January 21, 2000

[123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophreniaN P Verhoeff, J C Soares, C D D'Souza, et al.

Proceedings of the National Academy of Sciences of the United States of America|August 20, 1996

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjectsM Laruelle, A Abi-Dargham, C H van Dyck, et al.

Neurology|November 20, 2009

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseS Salloway, R Sperling, S Gilman, et al.

The Journal of Prevention of Alzheimer'S Disease|March 22, 2023

Investigating Partially Discordant Results in Phase 3 Studies of AducanumabC Mallinckrodt, Y Tian, P S Aisen, et al.

The Journal of Prevention of Alzheimer'S Disease|May 11, 2022

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseS Budd Haeberlein, P S Aisen, F Barkhof, et al.

The Journal of Prevention of Alzheimer'S Disease|October 1, 2024

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease TrialsS Walter, O Langford, G A Jimenez-Maggiora, et al.

Pageof 5